18F-Labeled Peptides: The Future Is Bright

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2014 Dec 11

PMID 25493636

Citations 51

Authors

Susan Richter

Frank Wuest

Affiliations

Soon will be listed here.

Abstract

Radiolabeled peptides have been the subject of intense research efforts for targeted diagnostic imaging and radiotherapy over the last 20 years. Peptides offer several advantages for receptor imaging and targeted radiotherapy. The low molecular weight of peptides allows for rapid clearance from the blood and non-target tissue, which results in favorable target-to-non-target ratios. Moreover, peptides usually display good tissue penetration and they are generally non-immunogenic. A major drawback is their potential low metabolic stability. The majority of currently used radiolabeled peptides for targeted molecular imaging and therapy of cancer is labeled with various radiometals like 99mTc, 68Ga, and 177Lu. However, over the last decade an increasing number of 18F-labeled peptides have been reported. Despite of obvious advantages of 18F like its ease of production in large quantities at high specific activity, the low β+ energy (0.64 MeV) and the favorable half-life (109.8 min), 18F-labeling of peptides remains a special challenge. The first part of this review will provide a brief overview on chemical strategies for peptide labeling with 18F. A second part will discuss recent technological advances for 18F-labeling of peptides with special focus on microfluidic technology, automation, and kit-like preparation of 18F-labeled peptides.

Citing Articles

Evaluation of [F]AlF NOTA-5G, an Aluminum [F]fluoride Labeled Peptide Targeting the Cell Surface Receptor Integrin Alpha(v)beta(6) for PET Imaging.

Hausner S, Davis R, Ganguly T, Harris R, Sutcliffe J Mol Imaging Biol. 2025; .

PMID: 39979580 DOI: 10.1007/s11307-025-01989-3.

Simple and Efficient Synthesis of -Succinimidyl-4-[F]fluorobenzoate ([F]SFB)-An Important Intermediate for the Introduction of Fluorine-18 into Complex Bioactive Compounds.

Orlovskaya V, Fedorova O, Viktorov N, Krasikova R Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770565 PMC: 11677304. DOI: 10.3390/ph17121723.

Optimization and Evaluation of AlF Labeling Using a NOTA-or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR.

Jeppesen T, Simon M, Torp J, Knudsen L, Leth J, Crestey F Front Nucl Med. 2024; 1:799533.

PMID: 39355634 PMC: 11440976. DOI: 10.3389/fnume.2021.799533.

(SiFA)SeFe: A Hydrophilic Silicon-Based Fluoride Acceptor Enabling Versatile Peptidic Radiohybrid Tracers.

Deiser S, Fenzl S, Konig V, Drexler M, Smith L, George M J Med Chem. 2024; 67(16):14077-14094.

PMID: 39115131 PMC: 11345769. DOI: 10.1021/acs.jmedchem.4c00924.

Hetero-Diels-Alder and CuAAC Click Reactions for Fluorine-18 Labeling of Peptides: Automation and Comparative Study of the Two Methods.

Maujean T, Ramanoudjame S, Riche S, Le Guen C, Boisson F, Muller S Molecules. 2024; 29(13).

PMID: 38999148 PMC: 11243578. DOI: 10.3390/molecules29133198.

References

Haubner R, Wester H, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman S . Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001; 42(2):326-36. View

Haubner R, Wester H, Weber W, Mang C, Ziegler S, Goodman S . Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001; 61(5):1781-5. View

Kolb H, Finn M, Sharpless K . Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001; 40(11):2004-2021. DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5. View

Bergmann R, Scheunemann M, Heichert C, Mading P, Wittrisch H, Kretzschmar M . Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs. Nucl Med Biol. 2002; 29(1):61-72. DOI: 10.1016/s0969-8051(01)00284-0. View

ODoherty M, Marsden P, Hart I, Marshall J, Bansal S . Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging. 2002; 29(6):754-9. DOI: 10.1007/s00259-001-0756-3. View

Rostovtsev V, Green L, Fokin V, Sharpless K . A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed Engl. 2002; 41(14):2596-9. DOI: 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4. View

Hopkins A, Groom C . The druggable genome. Nat Rev Drug Discov. 2002; 1(9):727-30. DOI: 10.1038/nrd892. View

Wester H, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau F . PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging. 2002; 30(1):117-22. DOI: 10.1007/s00259-002-1012-1. View

Wust F, Hultsch C, Bergmann R, Johannsen B, Henle T . Radiolabelling of isopeptide N epsilon-(gamma-glutamyl)-L-lysine by conjugation with N-succinimidyl-4-[18F]fluorobenzoate. Appl Radiat Isot. 2003; 59(1):43-8. DOI: 10.1016/s0969-8043(03)00161-1. View

10.

Reubi J . Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003; 24(4):389-427. DOI: 10.1210/er.2002-0007. View

11.

Sanchez-Crespo A, Andreo P, Larsson S . Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging. 2003; 31(1):44-51. DOI: 10.1007/s00259-003-1330-y. View

12.

Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G . Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med. 2004; 45(5):892-902. View

13.

Haubner R, Weber W, Beer A, Vabuliene E, Reim D, Sarbia M . Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005; 2(3):e70. PMC: 1069665. DOI: 10.1371/journal.pmed.0020070. View

14.

Mading P, Fuchtner F, Wust F . Module-assisted synthesis of the bifunctional labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate ([(18)F]SFB). Appl Radiat Isot. 2005; 63(3):329-32. DOI: 10.1016/j.apradiso.2005.03.005. View

15.

Vaidyanathan G, Zalutsky M . Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. Int J Rad Appl Instrum B. 1992; 19(3):275-81. DOI: 10.1016/0883-2897(92)90111-b. View

16.

Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M . Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med. 2006; 47(4):566-73. View

17.

Lee Y, Jeong J, Kim H, Chang Y, Kim Y, Hong M . An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK). Nucl Med Biol. 2006; 33(5):677-83. DOI: 10.1016/j.nucmedbio.2006.04.004. View

18.

Marik J, Hausner S, Fix L, Gagnon M, Sutcliffe J . Solid-phase synthesis of 2-[18F]fluoropropionyl peptides. Bioconjug Chem. 2006; 17(4):1017-21. DOI: 10.1021/bc0600564. View

19.

Schirrmacher R, Bradtmoller G, Schirrmacher E, Thews O, Tillmanns J, Siessmeier T . 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed Engl. 2006; 45(36):6047-50. DOI: 10.1002/anie.200600795. View

20.

Marik J, Sutcliffe J . Fully automated preparation of n.c.a. 4-[18F]fluorobenzoic acid and N-succinimidyl 4-[18F]fluorobenzoate using a Siemens/CTI chemistry process control unit (CPCU). Appl Radiat Isot. 2006; 65(2):199-203. DOI: 10.1016/j.apradiso.2006.06.007. View